FDA'S Latest Guidance On Risk Evaluation And Mitigation Strategy (REMS)

DESCRIPTION: 

A Risk Evaluation and Mitigation Strategy (REMS) is a vital drug safety initiative that the U.S. Food and Drug Administration (FDA) can mandate for specific medications with serious safety concerns, ensuring a careful balance between the benefits and risks of the medication. Unlike the standard medication labeling that informs healthcare stakeholders about potential risks, only a select few medications necessitate a REMS.

Importantly, REMS doesn't aim to mitigate all possible adverse events, which are communicated separately in the medication’s prescribing information to healthcare providers. Instead, REMS is laser-focused on preventing, monitoring, and managing specific serious risks. Through informed education and reinforcement, it strives to reduce the frequency and severity of these events, providing a targeted approach to enhancing medication safety. This webinar is your passport to understanding how REMS goes beyond mere risk mitigation.